6 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $20M | $2M | 32.5% | 12.4% | $660824 | — | $2M |
| 2024 | $14M | -$2M | 32.0% | -11.2% | -$446540 | $10M | $909716 |
| 2023 | $16M | $864722 | 32.8% | 6.4% | $582524 | $9M | $775686 |
| 2022 | $20M | $3M | 34.6% | 14.4% | -$3M | $16M | $2M |
| 2021 | $22M | $3M | 35.3% | 18.1% | $134982 | — | $484389 |
| 2020 | $11M | $2M | 39.9% | 22.1% | $2M | — | — |
How the market has priced HLP against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Hongli Group Inc.'s revenue has grown 11.9% per year, and net income declined 4.3% per year. These are computed facts, not advice.
As of FY2025, Hongli Group Inc. reported — of total debt against $2M of cash.
In FY2025, gross margin was 32.5%, operating margin 12.4%, and net margin 9.9%.
As of Jun '26, Hongli Group Inc. traded at a price-to-earnings ratio of about 18.8× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.